Esomeprazole

Generic Name
Esomeprazole
Brand Names
Nexium, Vimovo, Nexium Control
Drug Type
Small Molecule
Chemical Formula
C17H19N3O3S
CAS Number
119141-88-7
Unique Ingredient Identifier
N3PA6559FT
Background

Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison ...

Indication

Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions incl...

Associated Conditions
Duodenal Ulcer, Erosive Esophagitis, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Stress Ulcers, Upper Gastrointestinal Hemorrhage, Zollinger-Ellison Syndrome, Acute benign gastric ulcers, Develop NSAID-induced gastric ulcers, Maintenance of healing Erosive esophagitis, Postendoscopy Bleeding
Associated Therapies
-

Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis

Phase 4
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-12-06
Last Posted Date
2024-12-17
Lead Sponsor
Indonesia University
Target Recruit Count
216
Registration Number
NCT06720610
Locations
🇮🇩

Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia

🇮🇩

Hermina Kemayoran Hospital, Jakarta Pusat, DKI Jakarta, Indonesia

🇮🇩

Hermina Bekasi Hospital, Bekasi, Jawa Barat, Indonesia

and more 2 locations

Relative Bioavailability of NX-5948 Tablets Vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

First Posted Date
2024-12-04
Last Posted Date
2024-12-19
Lead Sponsor
Nurix Therapeutics, Inc.
Target Recruit Count
18
Registration Number
NCT06717269
Locations
🇺🇸

Celerion, Lincoln, Nebraska, United States

Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.

First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Xijing Hospital of Digestive Diseases
Target Recruit Count
548
Registration Number
NCT06603688
Locations
🇨🇳

Xijing Hosipital of Digestive Disease, Xian, Shaanxi, China

Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection

Phase 4
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-07-29
Last Posted Date
2024-07-29
Lead Sponsor
Shicai Ye
Target Recruit Count
196
Registration Number
NCT06526455
Locations
🇨🇳

Yellow River Sanmenxia Hospital, Sanmenxia, Henan, China

🇨🇳

The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China

🇨🇳

Maoming People's Hospital, Maoming, Guangdong, China

and more 1 locations

Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication

First Posted Date
2024-07-23
Last Posted Date
2024-07-23
Lead Sponsor
Xijing Hospital of Digestive Diseases
Target Recruit Count
558
Registration Number
NCT06514274
Locations
🇨🇳

Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China

A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood

Phase 1
Completed
Conditions
Interventions
First Posted Date
2024-05-17
Last Posted Date
2024-11-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
15
Registration Number
NCT06419660
Locations
🇩🇪

Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

First Posted Date
2024-04-22
Last Posted Date
2024-07-05
Lead Sponsor
Bayer
Target Recruit Count
21
Registration Number
NCT06378658
Locations
🇺🇸

Parexel Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2024-04-15
Last Posted Date
2024-07-24
Lead Sponsor
Cerevel Therapeutics, LLC
Target Recruit Count
20
Registration Number
NCT06366243
Locations
🇺🇸

Dilworth, Minnesota, Dilworth, Minnesota, United States

Metformin and Esomeprazole in Preterm Pre-eclampsia

First Posted Date
2024-04-11
Last Posted Date
2024-04-11
Lead Sponsor
Christiana Care Health Services
Target Recruit Count
4
Registration Number
NCT06359015
Locations
🇺🇸

Christianacare Health System, Newark, Delaware, United States

© Copyright 2024. All Rights Reserved by MedPath